These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20972697)

  • 1. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease.
    Mygind ND; Harutyunyan MJ; Mathiasen AB; Ripa RS; Thune JJ; Gøtze JP; Johansen JS; Kastrup J;
    Inflamm Res; 2011 Mar; 60(3):281-7. PubMed ID: 20972697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.
    Harutyunyan M; Gøtze JP; Winkel P; Johansen JS; Hansen JF; Jensen GB; Hilden J; Kjøller E; Kolmos HJ; Gluud C; Kastrup J
    Immunobiology; 2013 Jul; 218(7):945-51. PubMed ID: 23294528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease.
    Zheng JL; Lu L; Hu J; Zhang RY; Zhang Q; Chen QJ; Shen WF
    Atherosclerosis; 2010 Jun; 210(2):590-5. PubMed ID: 20056225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease.
    Mathiasen AB; Harutyunyan MJ; Jørgensen E; Helqvist S; Ripa R; Gøtze JP; Johansen JS; Kastrup J
    Scand J Clin Lab Invest; 2011 Sep; 71(5):439-47. PubMed ID: 21827355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased YKL-40 levels in patients with isolated coronary artery ectasia: an observational study.
    Erdoğan T; Kocaman SA; Çetin M; Durakoğlugil ME; Kırbaş A; Canga A; Yılmaz A; Doğan S; Çiçek Y
    Anadolu Kardiyol Derg; 2013 Aug; 13(5):465-70. PubMed ID: 23728225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease.
    Wang Y; Ripa RS; Johansen JS; Gabrielsen A; Steinbruchel DA; Friis T; Bindslev L; Haack-Sørensen M; Jørgensen E; Kastrup J
    Scand Cardiovasc J; 2008 Oct; 42(5):295-302. PubMed ID: 18615353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance.
    Rathcke CN; Johansen JS; Vestergaard H
    Inflamm Res; 2006 Feb; 55(2):53-9. PubMed ID: 16612564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome.
    Türkyılmaz K; Öner V; Kırbas A; Sevim MS; Sekeryapan B; Özgür G; Durmus M
    Eye (Lond); 2013 Jul; 27(7):854-9. PubMed ID: 23661157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of Guizhi Fuling Decoction on YKL-40 and hs-CRP of patients with non-ST segment elevation acute coronary syndrome].
    Pei Q; Sang WF; Zhao XD
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Feb; 33(2):186-90. PubMed ID: 23646472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
    Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
    Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus.
    Kim HM; Lee BW; Song YM; Kim WJ; Chang HJ; Choi DH; Yu HT; Kang E; Cha BS; Lee HC
    Cardiovasc Diabetol; 2012 Jul; 11():84. PubMed ID: 22809439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease.
    Vind I; Johansen JS; Price PA; Munkholm P
    Scand J Gastroenterol; 2003 Jun; 38(6):599-605. PubMed ID: 12825867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population.
    Andreassen M; Raymond I; Hildebrandt P; Kistorp C; Rathcke C; Vestergaard H; Faber J; Kristensen LO
    Inflamm Res; 2010 Jul; 59(7):503-10. PubMed ID: 20047081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy.
    Kadoglou NP; Kottas G; Lampropoulos S; Vitta I; Liapis CD
    Clin Drug Investig; 2014 Mar; 34(3):165-71. PubMed ID: 24307429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction.
    Hedegaard A; Ripa RS; Johansen JS; Jørgensen E; Kastrup J
    Scand J Clin Lab Invest; 2010 Apr; 70(2):80-6. PubMed ID: 20102300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of YKL-40 increases in patients with acute myocardial infarction.
    Nøjgaard C; Høst NB; Christensen IJ; Poulsen SH; Egstrup K; Price PA; Johansen JS
    Coron Artery Dis; 2008 Jun; 19(4):257-63. PubMed ID: 18480670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
    Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
    Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.
    Kastrup J; Johansen JS; Winkel P; Hansen JF; Hildebrandt P; Jensen GB; Jespersen CM; Kjøller E; Kolmos HJ; Lind I; Nielsen H; Gluud C;
    Eur Heart J; 2009 May; 30(9):1066-72. PubMed ID: 19270316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of serum YKL-40 levels with the presence and severity of coronary artery disease in patients with obstructive sleep apnea syndrome.
    Sui X; Gao C
    Clin Invest Med; 2013 Dec; 36(6):E306-11. PubMed ID: 24309227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.
    Blum A; Costello R; Samsel L; Zalos G; McCoy P; Csako G; Waclawiw MA; Cannon RO
    Isr Med Assoc J; 2009 Oct; 11(10):602-5. PubMed ID: 20077946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.